skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Zach McLellan, Jack Allen, and guest analysts Louisa Joseph and Michael Haydock discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast, including results for Gilead's new HIV flagship product; Biktarvy, and the US approval of the HIV drug Trogarzo, the first for salvage patients.

Topics covered in this episode include:

  • ODYSSEY CVOT results of Praluent - (SNY REGN AMGN) - 0:39
  • Phase III trial results from patients who switched to Biktarvy from ABC/3TC/DTG (GILD GSK)- 19:47
  • US approval of Trogarzo (TH) - 31:33
  • Phase II results from a study of MOR208 in DLBCL (MOR) - 41:28

Subscribe to this podcast here


Register for HIV webinar


Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: